MarketPeel
Insider Trading Intelligence
AS

Andrew Saik

ARVN
CHIEF FINANCIAL OFFICER · ARVINAS, INC. · CIK 0001616284
FILING MIX · LIFETIME73%/27%
BUYS
16
SELLS
6
TOTAL VALUE
$385.3K
COMPANIES
4
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
423,449
AVG SELL PX
$9.38
TRADE KIND
SHOWING 22 / 22
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
4 backtested trades · 8 horizons · 9 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Andrew Saik, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d4+75.00%+2.19%+1.35%+0.84%-0.71%
14d4+50.00%+6.82%+0.79%+10.26%+13.28%
30d4+50.00%+3.32%+1.49%+1.83%+2.33%
60d4(1 pending)+100.00%+0.98%+4.57%-3.59%-7.44%
90d4(1 pending)+100.00%-1.75%+10.00%-11.75%-12.61%
180d4(2 pending)+50.00%+33.50%+14.19%+19.31%+19.31%
1y4(2 pending)+0.00%-36.48%+29.12%-65.60%-65.60%
2y4(3 pending)+0.00%-95.04%+23.69%-118.72%-118.72%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ARVN · 187,432 shares · as of Jun 24, 2026
051,067102,134153,200204,26720252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 16 buys / 6 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ARVN
ARVINAS, INC.
SALE10b5-1
10b5-1 plan
5,696$8.16$46.5K187,432Jun 24, 2026Jun 24, 2026View →
MIST
MILESTONE PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
77,00077,000Jun 10, 2026Jun 12, 2026View →
ARVN
ARVINAS, INC.
SALE
Chief Financial Officer
11,139$9.94$110.7K193,128May 11, 2026May 13, 2026View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
67,00067,000Feb 26, 2026Mar 2, 2026View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
45,000204,267Feb 26, 2026Mar 2, 2026View →
ARVN
ARVINAS, INC.
SALE
Chief Financial Officer
5,134$11.89$61.0K159,267Feb 13, 2026Feb 18, 2026View →
ARVN
ARVINAS, INC.
SALE
Chief Financial Officer
5,700$7.61$43.4K164,401Jun 24, 2025Jun 24, 2025View →
MIST
MILESTONE PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
40,00040,000Jun 10, 2025Jun 12, 2025View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
59,600170,101May 9, 2025May 13, 2025View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
91,00091,000May 9, 2025May 13, 2025View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
74,96074,960Feb 13, 2025Feb 18, 2025View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
49,092110,501Feb 13, 2025Feb 18, 2025View →
MIST
MILESTONE PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
40,00040,000Aug 28, 2024Aug 29, 2024View →
MIST
MILESTONE PHARMACEUTICALS INC.
SALEGRANT
Stock grant
80,00080,000Jul 15, 2024Jul 17, 2024View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
61,40961,409Jun 24, 2024Jun 26, 2024View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
94,41894,418Jun 24, 2024Jun 26, 2024View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
3,017$3.36$10.1K116,468May 28, 2021Jun 2, 2021View →
VYNE
VYNE THERAPEUTICS INC.
SALE
Chief Financial Officer
762$6.84$5.2K113,451Mar 31, 2021Apr 2, 2021View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
29,213114,213Feb 22, 2021Feb 24, 2021View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
68,16268,162Feb 22, 2021Feb 24, 2021View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
40,000$1.46$58.5K340,000Sep 8, 2020Sep 8, 2020View →
PDSB
PDS BIOTECHNOLOGY CORP
PURCHASEGRANT
Stock grant
38,400$1.30$49.9K42,549Feb 14, 2020Feb 19, 2020View →
Other insiders · ARVN
Loading peer insiders…
About this filer
CIK 0001616284
ROLE
Chief Financial Officer
PRIMARY
ARVN
COMPANIES
4
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001616284DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback